Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | CES1 | P23141 | 2/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | ANPEP | P15144 | 6/20 | 0.36 |
| ▸ | AHR | P35869 | 1/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
| ▸ | TDP2 | O95551 | 1/20 | 0.33 |
| ▸ | CASP3 | P42574 | 1/20 | 0.33 |
| ▸ | CASP7 | P55210 | 1/20 | 0.33 |
| ▸ | CASP9 | P55211 | 1/20 | 0.33 |
| ▸ | CASP6 | P55212 | 1/20 | 0.33 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.33 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | DRD1 | P21728 | 1/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
| ▸ | DRD5 | P21918 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6630183 | 0.79 | CYP2A6 (0.46) | CYP1A2CYP2A6MAOACES1ANPEP | |
| SCHEMBL519697 | 0.77 | CYP2A6 (0.50) | CYP1A2CYP2A6MAOACES1BCHE | |
| SCHEMBL5548723 | 0.73 | MAPT (0.40) | PDK2TDP2CASP7ALDH1A1 | |
| SCHEMBL2086425 | 0.71 | TRPA1 (0.47) | CYP1A2CYP2A6MAOAMAOBDRD2 | |
| SCHEMBL1848440 | 0.71 | TRPA1 (0.38) | CYP1A2 | |
| SCHEMBL5780088 | 0.71 | MEN1 (0.44) | MAOAMAOBDRD2DRD1DRD5 | |
| SCHEMBL5366327 | 0.70 | MAOB (0.41) | CYP1A2MAOAMAOBALDH1A1 | |
| SCHEMBL14441607 | 0.68 | CYP1A2 (0.67) | CYP1A2CYP2A6MAOACES1BCHE | |
| SCHEMBL31392781 | 0.68 | CYP1A2 (0.67) | CYP1A2CYP2A6MAOACES1BCHE | |
| SCHEMBL77106 | 0.68 | CYP1A2 (1.00) | CYP1A2CYP2A6MAOACES1BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9296697-B2 | Hetaryl-substituted guanidine compounds and use thereof as binding partners for 5-HT5-receptors | ABBOTT LABORATORIES (US) | 2016-03-29 | — | — | US | disclosed |
| US-8642620-B2 | Heteroaryl-substituted amides comprising an unsaturated or cyclic linker group, and their use as pharmaceuticals | SANOFI (FR) | 2014-02-04 | — | — | US | disclosed |
| US-8518976-B2 | e.g. 1-(3-(6-(2-fluorophenyl)pyridin-3-yl)propyl)-1H-pyridin-2-one; endothelial nitric oxide NO synthase inhibitor; antiinflammatory, hypotensive agent; atherosclerosis, thrombosis, coronary artery disease, and cardiac insufficiency | SANOFI (FR) | 2013-08-27 | — | — | US | disclosed |
| EP-1899321-B1 | HETEROARYL-SUBSTITUTED AMIDES COMPRISING A SATURATED LINKER GROUP, AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2011-12-28 | — | — | EP | disclosed |
| EP-2379523-A1 | 4, 6-DISUBSTITUTED 2-AMINO-PYRIMIDINES AS HISTAMINE H4 RECEPTOR MODULATORS | Incyte Corporation (US) | 2011-10-26 | — | — | EP | disclosed |
| US-20100184787-A1 | Heataryl-substituted guanidine compounds and use thereof as binding partners for 5-ht5-receptors | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2010-07-22 | — | — | US | disclosed |
| WO-2010075270-A1 | 4, 6-DISUBSTITUTED 2-AMINO-PYRIMIDINES AS HISTAMINE H4 RECEPTOR MODULATORS | INCYTE CORPORATION (US) | 2010-07-01 | — | — | WO | disclosed |
| EP-1904476-B1 | HETEROARYL-SUBSTITUTED AMIDES COMPRISING AN UNSATURATED OR CYCLIC LINKER GROUP, AND THEIR USE AS PHARMACEUTICALS | SANOFI AVENTIS (FR) | 2009-02-25 | — | — | EP | disclosed |
| US-20080171739-A1 | Heteroaryl-Substituted Amides Comprising A Saturated Linker Group, And Their Use As Pharmaceuticals | SANOFI-AVENTIS (FR) | 2008-07-17 | — | — | US | disclosed |
| US-20080167342-A1 | Heteroaryl-Substituted Amides Comprising An Unsaturated Or Cyclic Linker Group, And Their Use As Pharmaceuticals | SANOFI-AVENTIS (FR) | 2008-07-10 | — | — | US | disclosed |
| WO-2007112347-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-10-04 | — | — | WO | disclosed |
| EP-1741708-A1 | Heteroaryl-substituted amides comprising an unsaturated or cyclic linker group, and their use as pharmaceuticals | Sanofi-Aventis Deutschland GmbH (DE) | 2007-01-10 | — | — | EP | disclosed |
| EP-1741709-A1 | Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals | Sanofi-Aventis Deutschland GmbH (DE) | 2007-01-10 | — | — | EP | disclosed |
| WO-2006108965-A2 | NPY ANTAGONISTS, PREPARATION AND USE | CEREP (FR) | 2006-10-19 | — | — | WO | disclosed |
| EP-0757986-B1 | Arylpiperidine and arylpiperazine derivatives and drugs containing the same | SUNTORY LTD (JP) | 2002-06-12 | — | — | EP | disclosed |
| US-20020068827-A1 | Quinoline-4-carboxamide derivatives, their preparation and their use as neurokinin 3 ( NK-3 ) - and neurokinin 2 ( NK-3 ) receptor antagonists | SMITHKLINE BEECHAM S.P.A. | 2002-06-06 | — | — | US | disclosed |
| EP-1019377-A1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS NEUROKININ 3 (NK-3)- AND NEUROKININ 2 (NK-2) RECEPTOR ANTAGONISTS. | Smithkline Beecham S.p.A. (IT) | 2000-07-19 | — | — | EP | disclosed |
| US-5723475-A | Arylpiperidine and arylpiperazine derivatives and medicament containing the same | SUNTORY LIMITED (JP) | 1998-03-03 | — | — | US | disclosed |
| WO-1997019926-A1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS NEUROKININ 3 (NK-3)- AND NEUROKININ 2 (NK-2) RECEPTOR ANTAGONISTS. | SMITHKLINE BEECHAM S.P.A. (IT) | 1997-06-05 | — | — | WO | disclosed |
| EP-0757986-A1 | ARYLPIPERIDINE AND ARYLPIPERAZINE DERIVATIVES AND DRUGS CONTAINING THE SAME | SUNTORY LIMITED (JP) | 1997-02-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171739-A1 | Heteroaryl-Substituted Amides Comprising A Saturated Linker Group, And Their Use As Pharmaceuticals | TBXAS1, PTGIS, NOS2 | CYP1A2 27/4885CYP2A6 336/4885MAOA 178/4885 |
| US-20080167342-A1 | Heteroaryl-Substituted Amides Comprising An Unsaturated Or Cyclic Linker Group, And Their Use As Pharmaceuticals | TBXAS1, PTGIS, NOS2 | CYP1A2 35/4885CYP2A6 280/4885MAOA 238/4885 |
| US-20020068827-A1 | Quinoline-4-carboxamide derivatives, their preparation and their use as neurokinin 3 ( NK-3 ) - and neurokinin 2 ( NK-3 ) receptor antagonists | TAC3, TACR2, TACR1 | CYP1A2 2673/4885CYP2A6 792/4885MAOA 2324/4885 |
| US-20100184787-A1 | Heataryl-substituted guanidine compounds and use thereof as binding partners for 5-ht5-receptors | HTR5A, HTR2C, HTR1E | CYP1A2 364/4885CYP2A6 1129/4885MAOA 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.